Free Trial
→ 'I'm risking my reputation on this' (From Crypto 101 Media) (Ad)

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
EWEB
Global X Emerging Markets Internet & E-commerce ETF
$21.14
$21.14
$18.42
▼
$25.54
$2.54M0.42469 shsN/A
NZUS
SPDR MSCI USA Climate Paris Aligned ETF
$32.54
+0.2%		$30.92
$26.06
▼
$34.03
$2.60M-1.1489 shs30 shs
ODDS
Pacer BlueStar Digital Entertainment ETF
$31.04
+0.8%		$28.61
$20.54
▼
$31.34
$1.86M-1.41556 shs1,045 shs
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
$7.38
$7.38
$5.87
▼
$11.83
$2.21M0.923,034 shsN/A
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
EWEB
Global X Emerging Markets Internet & E-commerce ETF
0.00%0.00%0.00%0.00%0.00%
NZUS
SPDR MSCI USA Climate Paris Aligned ETF
+0.25%+3.23%+3.05%+11.06%+6.48%
ODDS
Pacer BlueStar Digital Entertainment ETF
+0.51%+5.50%+7.16%+19.77%+43.86%
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
EWEB
Global X Emerging Markets Internet & E-commerce ETF
N/AN/AN/AN/AN/AN/AN/AN/A
NZUS
SPDR MSCI USA Climate Paris Aligned ETF
N/AN/AN/AN/AN/AN/AN/AN/A
ODDS
Pacer BlueStar Digital Entertainment ETF
N/AN/AN/AN/AN/AN/AN/AN/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
EWEB
Global X Emerging Markets Internet & E-commerce ETF
2.67
Moderate Buy$21.14N/A
NZUS
SPDR MSCI USA Climate Paris Aligned ETF
2.71
Moderate Buy$32.54N/A
ODDS
Pacer BlueStar Digital Entertainment ETF
2.79
Moderate Buy$31.04N/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
EWEB
Global X Emerging Markets Internet & E-commerce ETF
N/AN/AN/AN/AN/AN/A
NZUS
SPDR MSCI USA Climate Paris Aligned ETF
N/AN/AN/AN/AN/AN/A
ODDS
Pacer BlueStar Digital Entertainment ETF
N/AN/AN/AN/AN/AN/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
EWEB
Global X Emerging Markets Internet & E-commerce ETF
N/AN/A25.72∞N/AN/AN/AN/AN/A
NZUS
SPDR MSCI USA Climate Paris Aligned ETF
N/AN/A29.89∞N/AN/AN/AN/AN/A
ODDS
Pacer BlueStar Digital Entertainment ETF
N/AN/A25.22∞N/AN/AN/AN/AN/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/AN/A17.02∞N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
EWEB
Global X Emerging Markets Internet & E-commerce ETF
$0.060.28%N/AN/AN/A
NZUS
SPDR MSCI USA Climate Paris Aligned ETF
$1.795.50%N/AN/AN/A
ODDS
Pacer BlueStar Digital Entertainment ETF
$0.832.67%N/AN/AN/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/A0.12%N/AN/AN/A

Latest XDNA, NZUS, EWEB, and ODDS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/4/2025
ODDS
Pacer BlueStar Digital Entertainment ETF
Quarterly$0.64679.03%6/5/20256/5/20256/11/2025
5/30/2025
NZUS
SPDR MSCI USA Climate Paris Aligned ETF
Quarterly$0.09681.23%6/2/20256/2/20256/4/2025
(Data available from 1/1/2013 forward)

Institutional Ownership

CompanyInstitutional Ownership
EWEB
Global X Emerging Markets Internet & E-commerce ETF
N/A
NZUS
SPDR MSCI USA Climate Paris Aligned ETF
N/A
ODDS
Pacer BlueStar Digital Entertainment ETF
N/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/A

Insider Ownership

CompanyInsider Ownership
EWEB
Global X Emerging Markets Internet & E-commerce ETF
N/A
NZUS
SPDR MSCI USA Climate Paris Aligned ETF
N/A
ODDS
Pacer BlueStar Digital Entertainment ETF
N/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
EWEB
Global X Emerging Markets Internet & E-commerce ETF
N/A120,000N/ANo Data
NZUS
SPDR MSCI USA Climate Paris Aligned ETF
N/A80,000N/AOptionable
ODDS
Pacer BlueStar Digital Entertainment ETF
N/A60,000N/AOptionable
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/A300,000N/AOptionable

Recent News About These Companies

CHOP, Penn advance CRISPR gene editing with fast-developed treatment for an infant with a rare disease
May 15, 2025  |  msn.comhttps://www.msn.com/en-us/science/biology/chop-penn-advance-crispr-gene-editing-with-fast-developed-treatment-for-an-infant-with-a-rare-disease/ar-AA1EQMQr
Nobel Prize winners convince court to revive CRISPR patent dispute
May 12, 2025  |  reuters.comhttps://www.reuters.com/legal/government/nobel-prize-winners-convince-court-revive-crispr-patent-dispute-2025-05-12/
Biotech investors: Stop expecting CRISPR science to make big leaps
April 14, 2025  |  statnews.comS
AI and gene editing promise ‘bespoke proteins’ for biotech
October 8, 2024  |  siliconrepublic.comS
Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now
October 2, 2024  |  yahoo.comhttps://www.yahoo.com/tech/weight-loss-drug-breakthroughs-gene-090000589.html
K-12 Genome Editing at Only $2 a Pop
September 27, 2024  |  yahoo.comhttps://www.yahoo.com/tech/k-12-genome-editing-only-144035108.html
Vertex Stock: Came For CF Drugs, Staying For Gene Therapy
August 2, 2024  |  seekingalpha.comhttps://seekingalpha.com/article/4709620-vertex-stock-came-for-cf-drugs-staying-for-gene-therapy
CRISPR can treat common form of inherited blindness, early data hint
May 15, 2024  |  msn.comhttps://www.msn.com/en-gb/health/other/crispr-can-treat-common-form-of-inherited-blindness-early-data-hint/ar-BB1mrQQG
CRISPR gene editing: in summary
March 27, 2024  |  biotechniques.comB
CRISPR Technology Takes Center Stage at SXSW 2024 for the First Time
March 8, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/crispr-technology-takes-center-stage-at-sxsw-2024-for-the-first-time-1033147575
Intellia Collaborates With ReCode To Develop Gene Therapy For Cystic Fibrosis
February 15, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/intellia-collaborates-with-recode-to-develop-gene-therapy-for-cystic-fibrosis-1033071688
CRISPR Technology: Unveiling the Breakthrough in Gene Editing and Its Far-Reaching Implications
January 18, 2024  |  techbullion.comT
Here's Why CRISPR Therapeutics Stock Rose 54% Last Year
January 15, 2024  |  msn.comhttps://www.msn.com/en-us/money/other/here-s-why-crispr-therapeutics-stock-rose-54-last-year/ar-AA1n1jau
Gene editing is now a medical reality
December 8, 2023  |  news.yahoo.comhttps://news.yahoo.com/gene-editing-now-medical-reality-224326223.html
FDA approves first use of CRISPR gene editing to treat sickle cell disease
December 8, 2023  |  news.yahoo.comhttps://news.yahoo.com/fda-approves-first-crispr-gene-173254689.html
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
December 8, 2023  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/fda-approves-first-gene-editing-cell-therapy-for-sickle-cell-disease-an-inherited-blood-disorder-1032886628
Gene Editing Will Change Medicine—and Maybe Health Investing Too
November 24, 2023  |  msn.comhttps://www.msn.com/en-us/health/other/gene-editing-will-change-medicine-and-maybe-health-investing-too/ar-AA1ksQev
CRISPR/Cas9 unlocks TuMV resistance in Chinese cabbage: A leap forward in genome-edited plant breeding
November 23, 2023  |  phys.orgP
Is CRISPR Therapeutics the Best Gene-Editing Stock?
November 22, 2023  |  msn.comhttps://www.msn.com/en-us/money/other/is-crispr-therapeutics-the-best-gene-editing-stock/ar-AA1klNrx
Three people were gene-edited in an effort to cure their HIV. The result is unknown.
November 16, 2023  |  technologyreview.comT

Media Sentiment Over Time

Global X Emerging Markets Internet & E-commerce ETF NASDAQ:EWEB

$21.14 0.00 (0.00%)
As of 06/26/2025

The Global X Emerging Markets Internet & E-commerce ETF (EWEB) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks an index of companies positioned to benefit from the advancement of internet and e-commerce technologies in emerging market countries. EWEB was launched on Nov 9, 2020 and is managed by Global X.

SPDR MSCI USA Climate Paris Aligned ETF NASDAQ:NZUS

$32.54 +0.08 (+0.24%)
Closing price 06/27/2025 01:46 PM Eastern
Extended Trading
$32.54 +0.00 (+0.00%)
As of 06/27/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The SPDR MSCI USA Climate Paris Aligned ETF (NZUS) is an exchange-traded fund that is based on the MSCI USA Climate Paris Aligned index. The fund tracks a tier-weighted index of large- and mid-cap US stocks selected and weighted based on ESG criteria that are compatible with the Paris Climate Agreement and carbon reduction goals. NZUS was launched on Apr 21, 2022 and is managed by State Street.

Pacer BlueStar Digital Entertainment ETF NASDAQ:ODDS

$31.04 +0.24 (+0.79%)
Closing price 06/27/2025 03:35 PM Eastern
Extended Trading
$31.04 +0.00 (+0.00%)
As of 06/27/2025 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Pacer BlueStar Digital Entertainment ETF (ODDS) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a tier-weighted index of globally-listed companies that focuses on the digital entertainment industry, including online gambling, video gaming, content streaming, and eSports. ODDS was launched on Apr 8, 2022 and is managed by Pacer.

Kelly CRISPR & Gene Editing Technology ETF stock logo

Kelly CRISPR & Gene Editing Technology ETF NASDAQ:XDNA

$7.38 0.00 (0.00%)
As of 06/26/2025

The Strategic CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology. XDNA was launched on Jan 12, 2022 and is managed by Kelly.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas